Is the use of secukinumab after anti-TNF therapy greater than expected for the risk of developing inflammatory bowel disease? Fatih Albayrak; Mustafa Gür; Ahmet Karata¿; Süleyman Serdar Koca; Bünyamin K¿sac¿k;

Secukinumab como tratamiento biológico en la artritis psoriásica en práctica clínica real José A. Pinto Tasende; Francisco J. Maceiras Pan; José A. Mosquera Martínez; Luis Fernández Dominguez; Blanca Correa Rey; Carlos García Porrúa;

Elevated oxidative stress markers in patients with ankylosing spondylitis: A case¿control study Zouhour Gassara; Hela Fourati; Mariem Meseddi; Aida Elleuch; Afef Feki; Mohamed Hedi Kallel; Sofien Baklouti; Khansa Chaabouni; Fatma Ayadi;